Climb Bio and Mabworks report Phase 1 data supporting quarterly CLYM116/MIL116 dosing for IgA nephropathy

Climb Bio and Mabworks reported Phase 1 data supporting quarterly dosing of CLYM116/MIL116 for IgA nephropathy. A Phase 3 trial is expected in 2027.

Detected & updated continuously · Source: Nebula